問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5239Cases

2024-02-01 - 2038-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
0Sites

2024-04-01 - 2027-03-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2023-04-12 - 2028-04-12

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-01-12 - 2026-09-11

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-07-01 - 2024-06-28

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-06-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

  • Condition/Disease

    Differentiated Thyroid Cancer

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet

Participate Sites
4Sites

Recruiting4Sites

2016-07-21 - 2018-11-03

Phase II

A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

  • Condition/Disease

    ulcerative colitis

  • Test Drug

    PF-06480605

Participate Sites
4Sites

Terminated3Sites

2018-04-01 - 2020-01-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2016-04-01 - 2019-02-24

Phase II

A phase II study of autologous human dermal fibroblasts for the treatment of moderate to severe nasolabial fold wrinkles in adults

  • Condition/Disease

    moderate to severe nasolabial fold wrinkles

  • Test Drug

    無

Participate Sites
1Sites

Terminated1Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2018-01-01 - 2022-01-31

Phase I

A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease

  • Condition/Disease

    Moderate to Severe Chronic Kidney Disease (stage 3B to 4)

  • Test Drug

    ELIXCYTE

Participate Sites
3Sites

Recruiting3Sites

吳麥斯
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Nephrology

1 520 521 522 523 524
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB